Journal
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
Volume 7, Issue 9, Pages -Publisher
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/cshperspect.a024380
Keywords
-
Categories
Funding
- Wellcome Trust Intermediate Clinical Fellowship
- Wellcome-Beit award
- Oxford Biomedical Research Centre
- Alzheimer's Research UK ARUK
- UK Medical Research Council [U105184291]
- National Centre for the Replacement, Refinement AMP
- Reduction of Animals in Research (NC3R)
- Cambridge Biomedical Research Centre
- Engineering and Physical Sciences Research Council (EPSRC)
- British Medical Association (BMA)
- ARUK
- MRC [MC_U105184291] Funding Source: UKRI
- Alzheimers Research UK [ARUK-NSG2017-008, ARUK-PPG2015B-2] Funding Source: researchfish
- Medical Research Council [MC_U105184291] Funding Source: researchfish
- Parkinson's UK [G-1011, J-1403, J-0901, G-0701, G-1102] Funding Source: researchfish
Ask authors/readers for more resources
Parkinson's disease is the second most common neurodegenerative disorder, with only partial symptomatic therapy and no mechanism-based therapies. The accumulation and aggregation of alpha-synuclein is causatively linked to the sporadic form of the disease, which accounts for 95% of cases. The pathology is a result of a gain of toxic function of misfolded alpha-synuclein conformers, which can template the aggregation of soluble monomers and lead to cellular dysfunction, at least partly by interfering with membrane fusion events at synaptic terminals. Here, we discuss the transcellular propagation and intracellular trafficking of alpha-synuclein and posit that endosomal processing could be a point of convergence between these two routes. Understanding these events will clarify the therapeutic potential of enzymes that regulate protein trafficking and degradation in synucleinopathies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available